Australia - englanti - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

boucher & muir pty ltd - ropivacaine hydrochloride -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty limited - ropivacaine hydrochloride -

Australia - englanti - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - ropivacaine hydrochloride -

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 1 g;   - powder for injection - 1 g - active: flucloxacillin sodium monohydrate 1 g   - latest regulatory activity

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 250mg;   - powder for injection - 250 mg - active: flucloxacillin sodium monohydrate 250mg  

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

douglas pharmaceuticals limited - flucloxacillin sodium monohydrate 500mg;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 500mg  

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 100mg - film coated tablet - 100 mg - active: ritonavir 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry white 16b18449 sodium stearyl fumarate sorbitan laurate - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ropivacaine hydrochloride 10 mg/ml equivalent to ropivacaine 8.83 mg/ml - solution for injection - 10 mg/ml - active: ropivacaine hydrochloride 10 mg/ml equivalent to ropivacaine 8.83 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - surgical anaesthesia (adults and children over 12 years of age) · epidural block for surgery including caesarean section · intrathecal anaesthesia · field block (minor nerve block and infiltration) · major nerve block

Uusi-Seelanti - englanti - Medsafe (Medicines Safety Authority)

boucher & muir (new zealand) limited t/a bnm group - ropivacaine hydrochloride 2 mg/ml equivalent to ropivacaine 1.77 mg/ml - solution for injection - 2 mg/ml - active: ropivacaine hydrochloride 2 mg/ml equivalent to ropivacaine 1.77 mg/ml excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - surgical anaesthesia (adults and children over 12 years of age) · epidural block for surgery including caesarean section · intrathecal anaesthesia · field block (minor nerve block and infiltration) · major nerve block